Abstract: This invention is directed to substituted 4-phenoxy and 4-phenylthio prolines of the formula ##STR1## which possess useful hypotensive activity.

Abstract: Bicycloheptane substituted ether prostaglandin analogs are provided having the structural formula ##STR1## wherein X is O or ##STR2## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

Abstract: 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: Bicycloheptane substituted prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.

Abstract: Compounds of the formula ##STR1## are disclosed. They possess angiotensin converting enzyme inhibition activity and diuretic activity and are therefore useful as antihypertensive agents.

Abstract: 7-Oxabicycloheptane prostaglandin intermediates are provided having the general structure ##STR1## wherein one of R.sup.1 and R.sup.2 is ##STR2## and the other is hydrogen. A method for preparing the above intermediates is also provided. The final products are used in the treatment of thrombolytic disease.

Abstract: 7-Oxabicycloheptane prostaglandin intermediates are provided having the general structure ##STR1## wherein one of R.sup.1 and R.sup.2 is ##STR2## and the other is hydrogen. A method for preparing the above intermediates is also provided.

Abstract: Optically active 7-oxabicyclopheptane prostaglandin intermediates are provided having the general structure ##STR1## wherein one of R.sup.1 and R.sup.2 is ##STR2## and the other is hydrogen. A method for preparing the above intermediates is also provided.

Abstract: Carboxyalkyl dipeptides of the formula ##STR1## wherein R.sub.4 is a 3-, 4-, 5-, or 4,4-substituted proline are disclosed. These compounds are useful as hypotensive agents due to their angiotensin converting enzyme inhibition activity.

Abstract: A method is provided for preparing intermediates for use in prostacyclin syntheses which method includes the steps of aceylating ketopinic acid or its acid halide to form the corresponding ketopinoyl diene ester intermediate, subjecting the diene ester to a Diels-Alder reaction by reacting same with cyclopentendione, subjecting the resulting chiral ester intermediate to a fluorination and reduction to form the corresponding chiral ester diol intermediate, subjecting the diol to solvolysis to form the chiral triol intermediate, hydroxylating the chiral triol to form a pentol intermediate, subjecting the pentol to a ring cleavage to form the difluoro dihydroxy prostacyclin intermediate ##STR1## and subjecting same to a Witting reaction to form the difluoro dihydroxy prostacyclin intermediate ##STR2## All of the above-mentioned intermediates are novel compounds and thus are also provided.

Abstract: New dioxatricyclic prostacyclin analogs are provided which have the general formula ##STR1## wherein R is hydrogen or lower alkyl, Q is a single bond or --CH.sub.2 --, m is 1 to 9 and n is 3 or 4, and all stereoisomers thereof, and are useful as cardiovascular agents.

Abstract: A method is provided for preparing intermediates for use in prostacyclin syntheses which method includes the steps of aceylating ketopinic acid or its acid halide to form the corresponding ketopinoyl diene ester intermediate, subjecting the diene ester to a Diels-Alder reaction by reacting same with cyclopentendione, subjecting the resulting chiral ester intermediate to a fluorination and reduction to form the corresponding chiral ester diol intermediate, subjecting the diol to solvolysis to form the chiral triol intermediate, hydroxylating the chiral triol to form a pentol intermediate, subjecting the pentol to a ring cleavage to form the difluoro dihydroxy prostacyclin intermediate: ##STR1## and subjecting same to a Wittig reaction to form the difluoro dihydroxy prostacyclin intermediate: ##STR2## All of the above-mentioned intermediates are novel compounds and thus are also provided.

Abstract: New dioxatricyclic prostacyclin analogs are provided which have the general formula ##STR1## wherein R is hydrogen or lower alkyl, Q is a single bond or --CH.sub.2 --, m is 1 to 9 and n is 3 or 4, and all stereoisomers thereof, and are useful as cardiovascular agents.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, phenyl lower alkyl or halo substituted lower alkyl;R.sub.2 is hydrogen, lower alkyl, phenyl lower alkyl or halo substituted lower alkyl;n is 0, 1 or 2;X is --(CH.sub.2).sub.m Z--;Z is oxygen, sulfur or imino;m is 0 or 1;Y is S--R or ##STR2## R is hydrogen, lower alkyl, ##STR3## R.sub.3 is lower alkyl, phenyl or phenyl lower alkyl; and R.sub.4 is hydroxy, amino, hydroxyamino or lower alkoxy. These compounds are useful as hypotensive agents.

Abstract: A method is provided for preparing intermediates for use in 10,10-difluoro prostacyclin syntheses which method includes the steps of aceylating ketopinic acid or its acid halide to form the corresponding ketopinoyl diene ester intermediate, subjecting the diene ester to a Diels-Alder reaction by reacting same with cyclopentendione, subjecting the resulting chiral ester intermediate to a fluorination and reduction to form the corresponding chiral ester diol intermediate, subjecting the diol to solvolysis to form the chiral triol intermediate, hydroxylating the chiral triol to form a pentol intermediate, subjecting the pentol to a ring cleavage to form the difluoro dihydroxy prostacyclin intermediate ##STR1## and subjecting same to a Wittig reaction to form the difluoro dihydroxy prostacyclin intermediate ##STR2## All of the above-mentioned intermediates are novel compounds and thus are also provided.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, phenyl lower alkyl or halo substituted lower alkyl;R.sub.2 is hydrogen, lower alkyl, phenyl lower alkyl or halo substituted lower alkyl;n is 0, 1 or 2;X is--(CH.sub.2).sub.m Z--;Z is oxygen, sulfur or imino;m is 0 or 1;Y is S-R or ##STR2## R is hydrogen, lower alkyl, ##STR3## R.sub.3 is lower alkyl, phenyl or phenyl lower alkyl; and R.sub.4 is hydroxy, amino, hydroxyamino or lower alkoxy. These compounds are useful as hypotensive agents.

Abstract: New compounds having the general formula ##STR1## are useful as cardiovascular agents, and as intermediates for the preparation of compounds having the general formula ##STR2## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is --CHO--, CH.sub.2 OH or --CH.dbd.CH--R.sup.3 --lower alkylene--CH.sub.3 ; and R.sub.3 is keto or hydroxymethyl.